KRAS and colorectal cancer: KRAS point mutations have been studied in terms of pathogenesis and progression in colorectal cancers and their identification has recently been shown to be clinically useful as an indicator of cetuximab therapeutic effect, represented by overall survival and progression-free survival [6].